Home > Insider Trading > Filing (0001144204-14-027617)

Filing Details

Accession Number:: 0001144204-14-027617
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-05-05 18:02:22
Reporting Period:: 2014-05-01

Filing Date:: 2014-05-05
Accepted Time:: 2014-05-05 17:02:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1088856	Corcept Therapeutics Inc	CORT	Pharmaceutical Preparations (2834)	770487658

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	C/O Longitude Capital Partners, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-05-01	160,343	$4.12	12,595,325	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Disposition	2014-05-01	3,214	$4.12	174,691	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Common Stock	Disposition	2014-05-02	84,744	$4.07	12,510,581	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Disposition	2014-05-02	1,699	$4.07	172,992	No	4	S	Indirect	By Longitude Capital Associates, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.

Footnotes

Reflects sales of common stock executed in multiple transactions at prices ranging from $4.0700 to $4.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
Does not include warrants held by Longitude Venture Partners, L.P.("LVP") to purchase 3,091,479 shares of common stock.
Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. Patrick G. Enright is a managing member of Longitude Capital Partners, LLC("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein.
Does not include warrants held by LCA to purchase 26,583 shares of common stock.
Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P.("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein.
Reflects sales of common stock executed in multiple transactions at prices ranging from $4.0000 to $4.1100. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.